Total Laboratory Automation for Microbiology Activities: An HTA Analysis in an Italian Laboratory Setting [0.03%]
意大利实验室的微生物学活动的全实验室自动化-HTA分析研究
Emanuela Foglia,Elisabetta Garagiola,Lucrezia Ferrario et al.
Emanuela Foglia et al.
Objective: Microbiology laboratories face increasing challenges related to rising sample volumes, workforce constraints, and the need for improved diagnostic accuracy and efficiency. Total Laboratory Automation (TLA) has ...
First-Line Treatment of Chronic Lymphocytic Leukemia in Italy: Real-World Evidence on Utilization, Outcomes, and Healthcare Costs [0.03%]
意大利慢性淋巴细胞白血病的一线治疗：使用情况、结局和卫生保健费用的现实世界证据
Valentina Perrone,Vanessa Innao,Stefania Mazzoni et al.
Valentina Perrone et al.
Background: Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in Western countries, mainly affecting older people. Targeted agents have reshaped first-line (1L) strategies, making real-world evidence im...
Medical Claim Costs of Facioscapulohumeral Muscular Dystrophy in the United States [0.03%]
美国面肩肱型肌营养不良的医疗索赔成本
Amanda A Hill,June Kinoshita,Mariefel Nicole Deypalan et al.
Amanda A Hill et al.
Purpose: Facioscapulohumeral muscular dystrophy (FSHD) is a rare, progressive genetic disorder characterized by asymmetric muscle weakness and functional decline. Although it is one of the most common muscular dystrophies...
Cost-Effectiveness of Blinatumomab Plus Chemotherapy vs Chemotherapy in Adults Newly Diagnosed with Philadelphia-Negative B-Cell Acute Lymphoblastic Leukemia in Italy [0.03%]
意大利新近确诊的费城染色体阴性B细胞急性淋巴细胞白血病成人患者使用Blinatumomab联合化疗与单纯化疗的性价比分析
Gianni Ghetti,Luca Castello,Linet Awino Odonde et al.
Gianni Ghetti et al.
Background: While chemotherapy is the standard treatment for adults with newly diagnosed Philadelphia chromosome-negative (Ph-) B-cell precursor acute lymphoblastic leukemia (ALL), long-term remission remains difficult to...
The Cost-Effectiveness and Budget Impact Analysis of Upadacitinib for Moderate-to-Severe Atopic Dermatitis in Saudi Arabia [0.03%]
沙特阿拉伯中重度特应性皮炎患者使用乌帕替尼治疗的成本效益和预算影响分析
Nada Abu-Shraie,Afaf Al-Sheikh,Ibtisam Alharbi et al.
Nada Abu-Shraie et al.
Objective: Atopic dermatitis (AD) is a prevalent dermatological disease in Saudi Arabia. This study aimed to estimate the cost-effectiveness and budget impact of upadacitinib in adults and adolescents with moderate-to-sev...
Cancer Medication Consumptions in Vietnam Between 2019 and 2023: An Analysis from the National Database [0.03%]
越南2019-2023年癌症药物消耗量分析：来自国家数据库的数据
Mai Thi Tuyet Kieu,Duc Quang Tran,Anh Thi Phuong Le et al.
Mai Thi Tuyet Kieu et al.
Purpose: This study was conducted to analyse cancer medication consumption in Vietnam between 2019 and 2023. Materials and methods: Thi...
Real-World Clinical and Economic Outcomes Among Patients with Localized Prostate Cancer Undergoing Radical Prostatectomy Across Different Risk Stratifications in the United States [0.03%]
美国不同风险分层的局部前列腺癌根治术后患者的真实世界临床和经济结果
Neal Shore,Benjamin Lowentritt,Charmi Patel et al.
Neal Shore et al.
Background: Radical prostatectomy is a potentially curative treatment for localized prostate cancer (LPC), but there is limited literature comprehensively describing clinical and economic outcomes stratified by risk group...
Model-Based Cost-Effectiveness Analysis of Routine Omega-3 Testing and Targeted Supplementation to Reduce Early Preterm Birth in Australia Compared with Current Practice [0.03%]
与当前做法相比，基于模型的常规欧米茄-3筛查和目标补充以减少澳大利亚早产的成本效益分析
Hossein Haji Ali Afzali,Ecushla Linedale,Craig Martin et al.
Hossein Haji Ali Afzali et al.
Background: Preterm birth remains a leading cause of newborn death, disability, and long-term health challenges globally, with a substantial impact on families, the health system, and society. Omega-3 supplementation in w...
Samuel E Rasche,George O W Batchelor,Catharine Montgomery et al.
Samuel E Rasche et al.
Purpose: To assess the socioeconomic impact of increased uptake of long-acting injectable buprenorphine (LAIB) for opioid use disorder (OUD) in England. M...
Nivolumab-AVD versus Brentuximab Vedotin-AVD as First-Line Treatment for Advanced-Stage Classical Hodgkin Lymphoma: A Cost-Effectiveness Analysis [0.03%]
纳武单抗-AVD与贝林妥欧单抗-AVD作为经典型霍奇金淋巴瘤初治的一线疗法的成本效益分析
Biao Li,Jingjing Yang,Jing Li et al.
Biao Li et al.
Objective: To evaluate the cost-effectiveness of nivolumab plus doxorubicin/vinblastine/dacarbazine (N-AVD) versus brentuximab vedotin-AVD (BV-AVD) as first-line treatment for advanced-stage classical Hodgkin lymphoma. ...